Phase 2 N=20 Bexarotene Amyloid Treatment for Alzheimer's Disease
Alzheimer's Disease
Primary: Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain — -0.03; 0.02 SUVr — p=0.22
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants
Phase 1 N=315 Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Pertussis
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1. — 28; 31; 48; 18 IU/mL
Phase 3 N=572 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Primary: Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu) — 50.6; 42.4 percentage of participants — p=0.076
Phase 4 N=36 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
Psoriasis
Primary: Improvement in Quality of Life Measured by Change in Psychological General Well-Being Scale (PGWB) at Week 36 From Baseline. — 23.97 units on a scale
Phase 4 N=343 Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
Epilepsy
Primary: Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational…
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=6 Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Leukemia · Myelodysplastic Syndromes
Primary: Treatment Efficacy as Defined by Complete or Partial Remission — 1; 5 participants
Phase 3 N=417 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Overall Survival — 4.9; 4.2; 6.1; 4.2 months — p=0.9416
N/A N=100 Robotic Arm Assisted Total Knee Arthroplasty
Osteoarthritis · Rheumatoid Arthritis · Post-traumatic Arthritis
Primary: Intra-Operative Complications — 0 intra-operative complications
Phase 2 N=154 A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
Sarcoma
Primary: Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment — 52.5; 68.9 percentage of participants
Phase 3 N=229 Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 AUC (0-12h) Change From Patient Baseline After 6 Weeks of Treatment — 0.295; 0.317; 0.192; 0.188 Litres — p=<0.0001
N/A N=40 The Effect of Whole Almonds on Biomarkers of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: The Major Nutrients of NCEP Step 2 Diet and Almond Diets — 17.5; 17.2; 38.4; 29.2 % of energy — p=<0.0001
N/A N=375 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters
Phase 2 N=36 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Neoplastic Syndrome
Primary: Complete Response Rate — 2 Participants